

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Does respiratory infection due to *Chlamydia pneumoniae* still exist?

Authors: Senn L, Jaton K, Fitting JW, Greub G

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Year: 2011 Oct

Volume: 53

Issue: 8

Pages: 847-8

DOI: 10.1093/cid/cir515

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

Does respiratory infection due to *Chlamydia pneumoniae* still exist?

Laurence Senn^{1, 2}, Katia Jaton³, Jean-William Fitting⁴, Gilbert Greub*^{2, 3}

¹ Hospital Preventive Medicine, ² Infectious Diseases Service, ³ Institute of Microbiology, ⁴ Pneumology Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland

*Corresponding author:

Gilbert Greub, MD PhD

Center for Research on Intracellular Bacteria (CRIB),

Institute of Microbiology,

University of Lausanne

Lausanne, Switzerland

Phone: (00) 41 21 314 49 79

Fax: (00) 41 21 314 40 60

e-mail: gilbert.greub@chuv.ch

Word count: 491

Keywords: *Chlamydia pneumoniae*, respiratory infection, asthma

To the Editor: Since the late eighties, *Chlamydia pneumoniae* is considered as an agent of community-acquired pneumonia (CAP) and of other respiratory tract infections affecting all ages [1]. The common occurrence of *C. pneumoniae* infection is suggested by the high seroprevalence ($\geq 70\%$) observed in adults [2]. However, in recent studies [3-5], the prevalence of respiratory infections due to *C. pneumoniae* was reported to be much lower ($<1.5\%$) than previously (6-22%) [6]. This apparent decrease in *C. pneumoniae* infections prevalence could be due to changes in *C. pneumoniae* epidemiology over time, to increased specificity of new diagnostic methods or to the difficulty for clinicians to target the infected population.

In our university hospital, we routinely use a multiplex real-time PCR for the detection of *C. pneumoniae* and *Mycoplasma pneumoniae* DNA [7]. From October 2001 to June 2010, a total of 2244 respiratory specimens retrieved from 1583 patients were sent to the laboratory for *C. pneumoniae* and/or *M. pneumoniae* PCR, including 884 bronchoalveolar lavages, 843 nasopharyngeal swabs, 354 bronchial aspirates, 111 sputa and 52 other samples. Only 4 (0.2%) samples taken from two patients were positive for *C. pneumoniae*, whereas 76 (3.4%) were positive for *M. pneumoniae* in 65 patients. In both cases, the diagnosis of *C. pneumoniae* infection was not suspected by the clinician and the test was done thanks to the multiplex format of our molecular test.

The first patient with *C. pneumoniae* infection was a 48-year old man receiving immunosuppressive therapy for inflammatory bowel disease. He presented with a chronic cough initially suspected to be asthma and a febrile episode. PCRs performed on sputa obtained on day 0 and day 4 were highly positive with $2'285'300$ copies/ml (Ct=24.6) and $2'389'200$ copies/ml (Ct=25). The amount of DNA decreased to 465 copies/ml (Ct=37.2) in 17 days. In presence of persistent dry cough despite the falling bacterial load, clarithromycin 500 mg bid was administered for 2 weeks. Clinical evolution was favorable under

antimicrobial therapy with rapid decrease of cough. Follow-up PCRs at day 34 and day 48 were negative.

The second patient with *C. pneumoniae* infection was a healthy 13-year old girl presenting with a third episode of pneumonia over a 5-month period. PCR performed on naso-pharyngeal swab was positive with 153 copies/ml (Ct=36.5). The patient condition improved with clarithromycin therapy.

This study confirms that *C. pneumoniae* is rarely detected, at least in our setting, since only 2 patients out of 1583 were identified with *C. pneumoniae* infection over a ten-year period. This may reflect a low prevalence of the disease and/or suggests that clinicians do not target the right population. The 2nd hypothesis is supported by the fact that both cases were not suspected by the physician in charge and the etiological diagnosis was made thanks to the duplex approach of our molecular test. Since *C. pneumoniae* infection may be associated with persistent cough in adults [8, 9], it should be included in the differential diagnosis of chronic cough and asthma.

Acknowledgments

G.Greub is supported by the Leenards Foundation through a career award entitled “Bourse Leenards pour la relève académique en médecine clinique à Lausanne”.

References

- (1) Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. *J Infect Dis* 1990 Apr; 161(4):618-25.
- (2) Hermann C, Gueinzius K, Oehme A, Von AS, Straube E, Hartung T. Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydia pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections. *J Clin Microbiol* 2004 Jun; 42(6):2476-9.
- (3) Deng J, Zheng Y, Zhao R, Wright PF, Stratton CW, Tang YW. Culture versus polymerase chain reaction for the etiologic diagnosis of community-acquired pneumonia in antibiotic-pretreated pediatric patients. *Pediatr Infect Dis J* 2009 Jan; 28(1):53-5.
- (4) Stralin K, Tornqvist E, Kaltoft MS, Olcen P, Holmberg H. Etiologic diagnosis of adult bacterial pneumonia by culture and PCR applied to respiratory tract samples. *J Clin Microbiol* 2006 Feb; 44(2):643-5.
- (5) Weigl JA, Puppe W, Meyer CU, et al. Ten years' experience with year-round active surveillance of up to 19 respiratory pathogens in children. *Eur J Pediatr* 2007 Sep; 166(9):957-66.
- (6) Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. *Clin Infect Dis* 2007 Feb 15; 44(4):568-76.
- (7) Welti M, Jatton K, Altwegg M, Sahli R, Wenger A, Bille J. Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. *Diagn Microbiol Infect Dis* 2003 Feb; 45(2):85-95.
- (8) Miyashita N, Fukano H, Yoshida K, Niki Y, Matsushima T. Chlamydia pneumoniae infection in adult patients with persistent cough. *J Med Microbiol* 2003 Mar; 52(Pt 3):265-9.
- (9) Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjala H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. *Thorax* 1996 Feb; 51(2):185-9.